Renal calcium handling after rapamycin conversion in chronic allograft dysfunction.

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Calcium and phosphorus homeostasis are critical in transplant recipients.
• Rapamycin is an immunosuppressant with potential effects on mineral metabolism.
• Understanding these effects is crucial for managing long-term transplant outcomes.

Purpose of the Study:

• To investigate the impact of rapamycin conversion on calcium and phosphorus balance in transplant recipients.
• To assess changes in serum and urinary calcium and phosphorus levels, alkaline phosphatase, and intact parathyroid hormone (iPTH).

Main Methods:

• A prospective study involving transplant recipients converted to rapamycin.
• Comparison between a rapamycin conversion group (C) and a non-conversion group (N).
• Biochemical parameters (Urinary Ca, P, ALK-p, serum Ca, P, iPTH) were measured before and after 6 months.

Main Results:

• Rapamycin group showed increased alkaline phosphatase, serum calcium, urinary phosphorus excretion, and iPTH.
• Significant decreases were observed in serum phosphorus and urinary calcium excretion in the rapamycin group.
• Non-conversion group showed no significant changes in these parameters.

Conclusions:

• Rapamycin therapy is associated with significant alterations in calcium and phosphorus metabolism.
• Decreased urinary calcium and increased phosphorus excretion, along with elevated iPTH, suggest a potential impact on bone and mineral health.
• Further research is warranted to elucidate the mechanisms and clinical implications of these metabolic changes.